Companies /Healthcare

Doximity Inc - Class A

NYSE: DOCS Health Information Services
$27.08
▲ $0.76 (+2.89%) today
Markets open · 10:49am ET

Q2 2026 Earnings

Reported Nov 6, 2025, 4:08pm ET · SEC source
$0.45
Beat +18.70%
EPS · est. $0.38
$168.5M
Beat +6.94%
Revenue · est. $157.6M
−19.5%
Trailing market
DOCS vs S&P since report
2 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
−12%−6%0+6%Nov 6Nov 7report 4:08pm ETearnings+0.2%−9.2%
−12%−6%0+6%Nov 6Nov 7earnings+0.2%−9.2%
DOCS −9.2%S&P 500 +0.2%
−12%−6%0+6%Nov 6Nov 7report 4:08pm ETearnings−0.0%−9.2%
−12%−6%0+6%Nov 6Nov 7earnings−0.0%−9.2%
DOCS −9.2%NASDAQ −0.0%
−16%−8%0+8%Nov 5Nov 14report 4:08pm ETearnings+0.1%−15.9%
−16%−8%0+8%Nov 5Nov 14earnings+0.1%−15.9%
DOCS −15.9%S&P 500 +0.1%
−16%−8%0+8%Nov 5Nov 14report 4:08pm ETearnings−0.5%−15.9%
−16%−8%0+8%Nov 5Nov 14earnings−0.5%−15.9%
DOCS −15.9%NASDAQ −0.5%
−13.25%
Day of report
−3.22%
Next session
−8.60%
One week
−17.04%
30 days

S&P 500 over the same 30 days: +2.47%.

Did DOCS Beat Earnings? Q2 2026 Results

Doximity turned in a standout fiscal second quarter for 2026, posting revenue of $168.53 million — up 23.2% year-over-year and well ahead of the $157.59 million consensus — while non-GAAP diluted EPS of $0.45 beat the $0.38 estimate by 18.70%, reflecting the kind of operating leverage that has become a hallmark of the physician network platform. The single most material driver behind the beat was margin expansion: adjusted EBITDA reached $100.83 million, pushing margins to 59.8% from 55.7% a year ago, as revenue acceleration outpaced cost growth. AI engagement was a notable catalyst, with AI Scribe and DoxGPT users growing over 50% from the prior quarter and a record 650,000 prescribers tapping Doximity's workflow tools — a dynamic that stands in contrast to <a href="https://247wallst.com/investing/2025/12/04/docusign-shares-sell-off-despite-despite-strong-fy26-q3-earnings/">other software companies struggling</a> to translate strong results into investor confidence. Management raised full-year fiscal 2026 revenue guidance to $640–$646 million and guided Q3 revenue of $180–$181 million, signaling continued momentum through the seasonally important back half of the year.

Key Takeaways
  • Record 650,000 prescribers used workflow tools in Q2
  • AI Scribe and DoxGPT user growth over 50% quarter-over-quarter
  • 23% year-over-year revenue growth
  • Adjusted EBITDA margin expansion to 59.8% from 55.7% year-over-year
  • Non-GAAP net income margin expansion to 53.4% from 44.7% year-over-year

“Our platform continues to grow with new AI tools to save physicians' time.”

Doximity CEO, on the earnings call

Forward Guidance & Outlook

For fiscal Q3 2026 (ending December 31, 2025), Doximity guided revenue of $180 million to $181 million and adjusted EBITDA of $103 million to $104 million. For full fiscal year 2026 (ending March 31, 2026), the company updated guidance to revenue of $640 million to $646 million and adjusted EBITDA of $351 million to $357 million.

DOCS YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$50.0M$100.0M$150.0M$136.8M$168.5MRevenue$123.2M$152.1MGross Profit$53.1M$63.7MOperating Income$44.2M$62.1MNet Income
$0$50.0M$100.0M$150.0MRevenueGross ProfitOperating IncomeNet Income

DOCS Revenue by Segment

Subscription Revenue

Figures from SEC filings and company reports. Not investment advice.